To: | Quercis Pharma AG (summerfv@pepperlaw.com) |
Subject: | U.S. Trademark Application Serial No. 88836223 - KINISOQUIN - N/A |
Sent: | July 30, 2020 11:06:05 AM |
Sent As: | ecom130@uspto.gov |
Attachments: |
United States Patent and Trademark Office (USPTO)
Office Action (Official Letter) About Applicant’s Trademark Application
U.S. Application Serial No. 88836223
Mark: KINISOQUIN
|
|
Correspondence Address:
|
|
Applicant: Quercis Pharma AG
|
|
Reference/Docket No. N/A
Correspondence Email Address: |
|
NONFINAL OFFICE ACTION
The USPTO must receive applicant’s response to this letter within six months of the issue date below or the application will be abandoned. Respond using the Trademark Electronic Application System (TEAS). A link to the appropriate TEAS response form appears at the end of this Office action.
Issue date: July 30, 2020
This Office Action supersedes the previous Office Action dated 7/17/2020 in which the statement regarding conflicting marks below was inadvertently omitted.
The referenced application has been reviewed by the assigned trademark examining attorney. Applicant must respond timely and completely to the issue(s) below. 15 U.S.C. §1062(b); 37 C.F.R. §§2.62, 2.65(a); TMEP §§711, 718.03.
SUMMARY OF ISSUES:
· Identification of goods requirement
· Translation requirement
PROCEDURAL ISSUES
Identification of Goods Requirement
International Class 005: Applicant has identified the goods and/or services as “PHARMACEUTICAL PREPARATIONS INCLUDING THOSE FOR THE TREATMENT OF THROMBOSIS, SICKLE CELL DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, PANCREATIC CANCER, OVARIAN CANCER, EBOLA VIRUS AND COVID-19.”
The wording “including” in the identification of goods is indefinite and must be deleted and replaced with a definite term, such as “namely,” “consisting of,” “particularly,” or “in particular.” See 37 C.F.R. §2.32(a)(6); TMEP §§1402.01, 1402.03(a). The identification must be specific and all-inclusive. This wording is an open-ended term (e.g., “including,” “such as”) that is not acceptable because it fails to identify specific goods. See TMEP §1402.03(a).
The wording “pharmaceutical preparations” in the identification of goods is indefinite and must be clarified because the illness or matter being treated must be specified. See 37 C.F.R. §2.32(a)(6); TMEP §1402.01. Applicant must amend this wording to specify the common commercial or generic name of the goods. See TMEP §1402.01. If the goods have no common commercial or generic name, applicant must describe the product, its main purpose, and its intended uses. See id.
Applicant may substitute the following wording, if accurate:
Applicant’s goods and/or services may be clarified or limited, but may not be expanded beyond those originally itemized in the application or as acceptably amended. See 37 C.F.R. §2.71(a); TMEP §1402.06. Applicant may clarify or limit the identification by inserting qualifying language or deleting items to result in a more specific identification; however, applicant may not substitute different goods and/or services or add goods and/or services not found or encompassed by those in the original application or as acceptably amended. See TMEP §1402.06(a)-(b). The scope of the goods and/or services sets the outer limit for any changes to the identification and is generally determined by the ordinary meaning of the wording in the identification. TMEP §§1402.06(b), 1402.07(a)-(b). Any acceptable changes to the goods and/or services will further limit scope, and once goods and/or services are deleted, they are not permitted to be reinserted. TMEP §1402.07(e).
For assistance with identifying and classifying goods and services in trademark applications, please see the USPTO’s online searchable U.S. Acceptable Identification of Goods and Services Manual. See TMEP §1402.04.
English Translation Requirement
Applicant must submit an English translation of all foreign wording in the mark. 37 C.F.R. §2.32(a)(9); see TMEP §809. In the present case, the wording “KINISOQUIN” requires translation.
The following translation statement is suggested:
TMEP §809.03.
If this term has no meaning in a foreign language, applicant should provide the following statement:
Id.
RESPONSE GUIDELINES
Applicant should include the following information on all correspondence with the Office: (1) the name and law office number of the trademark examining attorney, (2) the serial number and filing date of the application, (3) the date of issuance of this Office action, (4) applicant’s name, address, telephone number and e-mail address (if applicable), and (5) the mark. 37 C.F.R. §2.194(b)(1); TMEP §302.03(a).
Please call or email the assigned trademark examining attorney with questions about this Office action. Although an examining attorney cannot provide legal advice, the examining attorney can provide additional explanation about the refusal(s) and/or requirement(s) in this Office action. See TMEP §§705.02, 709.06.
The USPTO does not accept emails as responses to Office actions; however, emails can be used for informal communications and are included in the application record. See 37 C.F.R. §§2.62(c), 2.191; TMEP §§304.01-.02, 709.04-.05.
How to respond. Click to file a response to this nonfinal Office action.
/mvaghani/
Mayur Vaghani
Trademark Examining Attorney
Law Office 130
Phone: (571) 272-1615
mayur.vaghani@uspto.gov
RESPONSE GUIDANCE